Terauchi Y, et al. - In study involving 63 patients, researchers tested the effectiveness and safety of tofogliflozin add-on to glucagon-like peptide-1 (GLP-1) receptor agonist monotherapy. Eligible study participants included Japanese patients who had already received GLP-1 receptor agonist monotherapy for ≥ 8 weeks, glycated hemoglobin ≥ 7.0 and < 10.5%, and body mass index ≥ 18.5 and < 35.0 kg/m². Tofogliflozin 20 mg was given with GLP-1 receptor agonist once daily to participants for 52 weeks. According to findings, tofogliflozin add-on to GLP-1 receptor agonist monotherapy is an effective treatment option, with an acceptable safety profile. The investigators observed significant improvement in fasting plasma glucose, body weight, and blood pressure levels among participants. Constipation, thirst, dehydration, and pollakiuria, however, were reported adverse events.